- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
By Chris Roberts for CannabisNow
“The committee staff will consider new information related to the cannabis plant, resin, extracts and tinctures,” [Steph] Sherer said. “Staff will also consider the emerging science related to THC and CBD.”
The United Nations’ 1961 Single Convention on Narcotic Drugs — the first international treaty to prohibit cannabis — has been at the center of over fifty years of global suffering caused by the failed “War on Drugs.” As decriminalization and other reforms take hold across the planet, safe access advocates are setting their sights on this cornerstone of global prohibition.
What’s the biggest impediment to worldwide reform on marijuana policy? If you guessed “the Controlled Substances Act,” the law passed by the United States Congress that deems cannabis a highly addictive substance with no medical value, you’d be wrong.
Before Richard Nixon used reefer madness as a political tool to marginalize his sworn enemies—i.e., black people and the left—the U.S. signed onto an international treaty called the “UN Single Convention on Narcotic Drugs.”
A total of 185 countries have signed onto the treaty, which lists cannabis, along with heroin, cocaine and a host of opiates, as a Schedule 1 narcotic years before the U.S. federal government did the same.
A dose of irony can be found in the fact that the treaty was ratified by the U.S. during the administration of John F. Kennedy, who took a wide-ranging cocktail of drugs for a host of ailments including pain and irritable bowel syndrome — both of which are relieved by medicinal cannabis.
Because of this document, nearly every country on earth agrees (at least officially) that marijuana is a bad, bad thing.
In the decades since, the U.N. treaty has been a useful weapon in the war on drugs, serving as an excuse to stymie drug policy reform—such as when the George W. Bush administration successfully bullied Canada’s Liberal government into abandoning a cannabis decriminalization effort in 2003.
Meanwhile, as medical marijuana has become available in more than half of America — with recreational marijuana available or soon to be available in 65 million people in eight states — the U.S. has made a total mockery of the treaty.
That could be why, as Canada’s federal government licensed medical marijuana producers and Prime Minister Justin Trudeau’s current Liberal government slowly but surely lays the groundwork to legalize cannabis in that country, the U.S., including President-elect Donald Trump’s crew, has made barely a peep.
On every level, things are ripe for a change—and a World Health Organization committee is making the first moves towards changing cannabis’s status internationally.
The reform advocates at Americans for Safe Access first took note that the WHO’s Expert Committee on Drug Dependence, an influential group of international policy-makers, want to “pre-review” marijuana’s classification and possibly recommend an examination that will lead to change.
ASA’s Steph Sherer said this will all happen within the next 18 months.
“The committee staff will consider new information related to the cannabis plant, resin, extracts and tinctures,” Sherer said. “Staff will also consider the emerging science related to THC and CBD.”
That’s a glacial pace compared to the speed at which cannabis reform is happening in the U.S. and elsewhere—including Israel, which is making plans to export medical marijuana within a few calendar years. But that’s how the process works.
In order for the UN General Assembly to amend the treaty on narcotic drugs, it needs a recommendation from the UN Commission on Narcotic Drugs. That commission, in turn, listens to the expert committee, which is just beginning to prepare to look at the issue.
And you thought the DMV was an intransigent bureaucracy.
Most experts are beyond bullish on further cannabis reform, and with the momentum from November’s near-sweep of marijuana reform initiatives — successful even in red states — some guess that marijuana will be legal across the U.S. within a decade.
Will the U.N. catch up by then? It’d be nice, but it might not matter. Still, better late than never.